Falcon Point Capital’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Falcon Point Capital’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	$291K	Sell	3,980 -186	-4%	-$13.8K	2.45%	15
2020 Q3	$324K	Buy	+4,166	New	+$287K	3.66%	5

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Falcon Point Capital's HZNP Position: Q4 2020 in Review

Falcon Point Capital reduced its Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) stake by 4.5% in Q4 2020, selling an estimated $13.8K and leaving 3,980 shares worth $291K. The position accounts for 2.45% of the portfolio, ranked #15.

Falcon Point Capital first reported a position in HZNP in Q3 2020 and has held it in 2 quarters since. The position peaked at $324K in Q3 2020. 497 funds tracked by Wall St. Rank hold HZNP as of Q4 2020.

Falcon Point Capital held 3,980 shares of Horizon Therapeutics Public Limited Company Ordinary Shares worth $291K as of Q4 2020.
Falcon Point Capital sold 186 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2020, an estimated $13.8K.
Horizon Therapeutics Public Limited Company Ordinary Shares made up 2.45% of Falcon Point Capital's portfolio in Q4 2020, its #15 holding.
Falcon Point Capital first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2020 and has held it in 2 quarters since.
Falcon Point Capital's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $324K in Q3 2020.
497 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2020.

Based on Falcon Point Capital's 13F filing for Q4 2020, filed 29 Jan 2021.